These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 27362942)
21. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Yu J; Kane S; Wu J; Benedettini E; Li D; Reeves C; Innocenti G; Wetzel R; Crosby K; Becker A; Ferrante M; Cheung WC; Hong X; Chirieac LR; Sholl LM; Haack H; Smith BL; Polakiewicz RD; Tan Y; Gu TL; Loda M; Zhou X; Comb MJ Clin Cancer Res; 2009 May; 15(9):3023-8. PubMed ID: 19366827 [TBL] [Abstract][Full Text] [Related]
22. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986 [TBL] [Abstract][Full Text] [Related]
23. Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells. Su Z; Yin J; Zhao L; Li R; Liang H; Zhang J; Wang K World J Surg Oncol; 2014 Dec; 12():367. PubMed ID: 25441176 [TBL] [Abstract][Full Text] [Related]
24. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947 [TBL] [Abstract][Full Text] [Related]
25. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells. Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905 [TBL] [Abstract][Full Text] [Related]
26. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Kobayashi S; Shimamura T; Monti S; Steidl U; Hetherington CJ; Lowell AM; Golub T; Meyerson M; Tenen DG; Shapiro GI; Halmos B Cancer Res; 2006 Dec; 66(23):11389-98. PubMed ID: 17145885 [TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; BarĂ³n A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836 [TBL] [Abstract][Full Text] [Related]
28. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Sharifnia T; Rusu V; Piccioni F; Bagul M; Imielinski M; Cherniack AD; Pedamallu CS; Wong B; Wilson FH; Garraway LA; Altshuler D; Golub TR; Root DE; Subramanian A; Meyerson M Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18661-6. PubMed ID: 25512530 [TBL] [Abstract][Full Text] [Related]
29. Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. Dong QZ; Wang Y; Tang ZP; Fu L; Li QC; Wang ED; Wang EH Am J Pathol; 2013 Mar; 182(3):954-64. PubMed ID: 23306155 [TBL] [Abstract][Full Text] [Related]
30. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers. Shien K; Ueno T; Tsukuda K; Soh J; Suda K; Kubo T; Furukawa M; Muraoka T; Maki Y; Tanaka N; Yamamoto H; Kiura K; Mitsudomi T; Toyooka S; Miyoshi S Clin Lung Cancer; 2012 Nov; 13(6):488-93. PubMed ID: 22503506 [TBL] [Abstract][Full Text] [Related]
31. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039 [TBL] [Abstract][Full Text] [Related]
32. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863 [TBL] [Abstract][Full Text] [Related]
33. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y; Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428 [TBL] [Abstract][Full Text] [Related]
34. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390 [TBL] [Abstract][Full Text] [Related]
35. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer. Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384 [TBL] [Abstract][Full Text] [Related]
36. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322 [TBL] [Abstract][Full Text] [Related]
37. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil. Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586 [TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer. Vora HH; Patel NA; Thakore PM; Shukla SN Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):653-60. PubMed ID: 25789532 [TBL] [Abstract][Full Text] [Related]
39. Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan. Liu HP; Isaac Wu HD; Chang JW; Wu YC; Yang HY; Chen YT; Hsieh WY; Chen YT; Chen YR; Huang SF J Thorac Oncol; 2010 Aug; 5(8):1175-84. PubMed ID: 20559151 [TBL] [Abstract][Full Text] [Related]
40. EGFR and erbB2 mutation status in Japanese lung cancer patients. Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]